Davita reported $3.6B in revenue (+4.6% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 1 open management expectation for this company. 1 insider sale recorded.
Notable transactions by executives and major shareholders from October 24 to October 30: market purchases, sales, and announced plans to sell shares. Disclosure does not indicate how an insider values a company and is not a recommendation to buy or sell.
DaVita Inc. released results for the third quarter of 2026: revenue was $3.578 billion, and operating income was $499 million. The data reflect the company's financial position for the reporting period ended September 30, 2026.
DAVITA INC.: 12 recorded developments from 1 official source in 2026-10.
2026-10-29: Revenue (us-gaap:Revenues), quarter 2026-07-01 to 2026-09-30: 3,578,126,000 USD (3.6 billion; 3,578 million); same period a year earlier (2025-07-01 to 2025-09-30): 3,420,227,000 USD (3.4 billion; 3,420 million); change +4.6%Source
2026-10-29: Revenue (us-gaap:Revenues), year to date 2026-01-01 to 2026-09-30: 10,547,758,000 USD (10.5 billion; 10,548 million); same period a year earlier (2025-01-01 to 2025-09-30): 10,023,282,000 USD (10 billion; 10,023 million); change +5.2%Source
2026-10-29: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 499,255,000 USD (499 million); same period a year earlier (2025-07-01 to 2025-09-30): 505,767,000 USD (506 million); change -1.3%Source
2026-10-29: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-30: 1,560,148,000 USD (1.6 billion; 1,560 million); same period a year earlier (2025-01-01 to 2025-09-30): 1,482,545,000 USD (1.5 billion; 1,483 million); change +5.2%Source
2026-10-29: Net income (us-gaap:NetIncomeLoss), quarter 2026-07-01 to 2026-09-30: 222,931,000 USD (223 million); same period a year earlier (2025-07-01 to 2025-09-30): 150,332,000 USD (150 million); change +48.3%Source
2026-10-29: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 685,858,000 USD (686 million); same period a year earlier (2025-01-01 to 2025-09-30): 512,586,000 USD (513 million); change +33.8%Source
2026-10-29: Diluted EPS (us-gaap:EarningsPerShareDiluted), year to date 2026-01-01 to 2026-09-30: 10.27 USD/shares; same period a year earlier (2025-01-01 to 2025-09-30): 6.62 USD/shares; change +55.1%Source
2026-10-29: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 1,329,730,000 USD (1.3 billion; 1,330 million); same period a year earlier (2025-01-01 to 2025-09-30): 1,345,774,000 USD (1.3 billion; 1,346 million); change -1.2%Source
2026-10-29: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), year to date 2026-01-01 to 2026-09-30: 431,323,000 USD (431 million); same period a year earlier (2025-01-01 to 2025-09-30): 430,434,000 USD (430 million); change +0.2%Source
2026-10-29: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 495,629,000 USD (496 million); previous balance (2025-12-31): 676,438,000 USD (676 million); change -26.7%Source
2026-10-29: Total assets (us-gaap:Assets), as of 2026-09-30: 17,816,512,000 USD (17.8 billion; 17,817 million); previous balance (2025-12-31): 17,480,103,000 USD (17.5 billion; 17,480 million); change +1.9%Source
2026-10-29: Total liabilities (us-gaap:Liabilities), as of 2026-09-30: 16,690,695,000 USD (16.7 billion; 16,691 million); previous balance (2025-12-31): 16,321,665,000 USD (16.3 billion; 16,322 million); change +2.3%Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Key figures
From the 10-Q for the period ended September 30, 2026, filed October 29, 2026. SEC
Latest
Earlier
Change
Revenue quarter
$3.6B
$3.4B
+4.6%
Operating income quarter
$499M
$506M
-1.3%
Net income quarter
$223M
$150M
+48.3%
Diluted EPS quarter
$3.40
$2.04
+66.7%
Operating cash flow year to date
$1.3B
$1.3B
-1.2%
Cash and cash equivalents balance
$496M
$676M
-26.7%
Next results expected around January 28, 2027 (estimate: the quarter ending about December 30, 2026 plus the 29 days the last report took). The company announces the actual date.
As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV
Revenue by quarter, $B
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
The company expects to offer expanded HD to the vast majority of its eligible patients in November.
Said October 29, 2026 · Period named: November · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.